Enzalutamide in biochemically recurrent prostate cancer: key findings from the EMBARK study
Sign Up to like & getrecommendations! Published in 2025 at "Future Oncology"
DOI: 10.1080/14796694.2025.2479331
Abstract: ABSTRACT This podcast features two of the investigators from the international, randomized, phase 3 EMBARK trial (NCT02319837) in conversation. EMBARK evaluated the efficacy and safety of enzalutamide plus androgen deprivation therapy and enzalutamide monotherapy, as… read more here.
Keywords: prostate cancer; embark; enzalutamide biochemically; biochemically recurrent ... See more keywords
Therapeutic modalities of deferiprone in Parkinson's disease: SKY and EMBARK studies
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Parkinson's Disease"
DOI: 10.1177/1877718x241300295
Abstract: Background Reducing nigrostriatal iron overload reduces neuronal loss in Parkinson's disease (PD) models. Objective Examine the safety and efficacy of deferiprone in reducing motor disability progression in dopaminergic-treated and treatment-naïve patients with early-stage PD. Methods… read more here.
Keywords: disease; embark; deferiprone; language ... See more keywords
Incidence of EMBARK and EAU high-risk biochemical recurrence and prostate cancer mortality: A real-life population-based study.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.5_suppl.372
Abstract: 372 Background: The EMBARK trial proved the efficacy of enzalutamide plus leuprolide in patients with prostate cancer (PCa) who have had high-risk biochemical recurrence (BCR). Different criteria are currently used to define high-risk BCR. The… read more here.
Keywords: embark; risk bcr; risk; high risk ... See more keywords